Author

Rachel Barger

Observed name: R. Barger

Institution: Keros Therapeutics (United States)

Observed institutions: Acceleron Pharma (United States), Keros Therapeutics (United States)

OpenAlex ID: A5048814955

Sotatercept in patients with osteolytic lesions of multiple myeloma

2014 · Kudrat M. Abdulkadyrov, Galina N. Salogub, et al. · British Journal of Haematology · 129

Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants

2020 · Claudia Ordonez, Snyder Ben, et al. · Blood · 5

A Phase 2, Randomized, Placebo-Controlled, Multiple Ascending-Dose Study of ACE-031, a Soluble Activin Receptor Type IIB, in Boys with Duchenne Muscular Dystrophy (DMD) (P04.088)

2012 · C. Campbell, D. Escolar, et al. · Neurology · 5

P3.18 A Phase 1 multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators, in healthy volunteers

2010 · N.G. Borgstein, R. Barger, et al. · Neuromuscular Disorders · 5

Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.

2013 · Michael B. Atkins, Rupal Satish Bhatt, et al. · Journal of Clinical Oncology · 1

P4.9 A phase 2, randomized, placebo-controlled, multiple ascending-dose study of ACE-031 (ActRIIB-IgG1) in Duchenne muscular dystrophy (DMD): Preliminary results

2011 · C. Campbell, K.M. Attie, et al. · Neuromuscular Disorders

Works count: 7

Citation count: 145

H-index: 4

I10-index: 1